SRRK
Scholar Rock Holding Corporation
NASDAQ · USHealthcareBiotechnology
$50.66-4.16%
Price as of Jul 20, 2026
SRRK financials
Scholar Rock Holding Corporation financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $0.00 | $0.00 | $33.2M |
| Cost of revenue | $208.4M | $1.9M | $2.8M | $123.0M |
| Gross profit | -$208.4M | -$1.9M | -$2.8M | -$89.9M |
| Operating expenses | $176.2M | $250.1M | $168.5M | $44.5M |
| Operating income | -$384.6M | -$252.1M | -$171.3M | -$134.4M |
| Net income | -$377.9M | -$246.3M | -$165.8M | -$134.5M |
| EBITDA | -$369.4M | -$237.5M | -$162.9M | -$129.5M |
| Basic EPS | $-3.29 | $-2.47 | $-1.99 | $-2.21 |
| Diluted EPS | $-3.29 | $-2.47 | $-1.99 | $-2.21 |
| Balance sheet | ||||
| Cash & equivalents | $323.5M | $177.9M | $101.9M | $103.3M |
| Total assets | $404.3M | $474.9M | $311.0M | $358.2M |
| Total liabilities | $158.8M | $106.3M | $85.8M | $97.9M |
| Stockholders’ equity | $245.5M | $368.6M | $225.2M | $260.2M |
| Total debt | $108.9M | $65.1M | $61.8M | $69.4M |
| Net debt | -$214.6M | -$112.8M | -$40.0M | -$33.9M |
| Cash flow | ||||
| Operating cash flow | -$300.0M | -$200.9M | -$145.2M | -$132.7M |
| Capital expenditure | -$602.0K | -$98.0K | -$71.0K | -$1.1M |
| Free cash flow | -$300.6M | -$201.0M | -$145.3M | -$133.8M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |